ASPM and microcephalin in ovarian cancer
Author Information
Author(s): Brüning-Richardson A, Bond J, Alsiary R, Richardson J, Cairns D A, McCormack L, Hutson R, Burns P, Wilkinson N, Hall G D, Morrison E E, Bell S M
Primary Institution: Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, UK
Hypothesis
ASPM and microcephalin might have a role in the tumorigenesis of high-grade epithelial ovarian cancer.
Conclusion
ASPM and microcephalin may serve as potential biomarkers in ovarian cancer.
Supporting Evidence
- High levels of cytoplasmic ASPM correlate with grade 1 tumours.
- Cytoplasmic microcephalin is only identified in high-grade tumours.
- Low levels of nuclear microcephalin correlate with reduced patient survival.
Takeaway
This study looked at two proteins, ASPM and microcephalin, in ovarian cancer to see if they can help doctors understand how serious the cancer is and how long patients might live.
Methodology
Protein levels of ASPM and microcephalin were analyzed in ovarian cancer cell lines and primary cultures derived from ascites using slot blotting and immunofluorescence.
Potential Biases
Potential bias in patient selection and sample processing could affect the results.
Limitations
The study's findings should be interpreted cautiously due to the variability in protein localization and the small sample size.
Participant Demographics
The mean age of participants was 62.2 years, with 87.5% over 50 years old.
Statistical Information
P-Value
0.036
Confidence Interval
(0.486, 8.473)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website